- Netflix: The Biggest Empty Promise Since Enron?
- Why Car Prices Vary From City To City
- Big Bank Phobia: Not Too Big to Fail
- Apple Should Still Fire Tim Cook
- Expect Your Health Care in Retirement to Hit $200,000
Article
A Buysider's Preview of Biotech's Biggest Conference
Nate Sadeghi breaks down next week's J.P. Morgan Healthcare Conference.
07:00AM 01/02/13
Article
Breaking Up With Gilead Sciences
Gilead is a great company and stock, but expectations are high and outperformance in 2013 will be tough.
07:00AM 12/17/12
Article
Time For Common Sense Gun Control Has Arrived
The tragedy in Newtown should bring gun owners and opponents together.
06:30AM 12/17/12
Article
Sarepta Is Still A Buy: Recent Concerns Much Ado About Nothing
Eteplirsen is a blockbuster drug for DMD, a view bolstered by Friday's 62-week data.
09:00AM 12/10/12
Article
Thoughts on Bio-Pharma Investor Sentiment Going Into 2013
Medical innovation is increasing but ever-escalating drug prices aren't sustainable.
07:00AM 12/03/12
Article
Nate Sadeghi's 2012 Biotech Stock Report Card
TheStreet columnist takes a look back at his best and worst biotech stock calls in 2012.
07:00AM 11/26/12
Article
Seattle Genetics: A Short Thesis That's Been Right And Wrong
Sales of the cancer drug Adcetris have fallen short but Seattle Genetics' stock price climbs higher.
07:00AM 11/12/12
Article
Arena Pharma Is Still A Good Short
A marginal effective weight-loss pill sold into an overhyped market by a mediocre partner makes Arena a short.
07:00AM 11/05/12
Article
Achillion Pharma Worthy of New Look
The winnowing of competing hepatitis C drugs has made Achillion's pipeline more compelling.
08:16AM 10/31/12
Article
United Therapeutics Could Lose The Battle For PAH Therapies
An FDA decision expected this week could easily go against United Therapeutics.
07:00AM 10/22/12